大腸菌感染症:治療薬開発パイプライン分析

【英語タイトル】Escherichia coli Infections - Pipeline Review, H2 2017

Global Markets Directが出版した調査資料(GMDHC9885IDB)・商品コード:GMDHC9885IDB
・発行会社(調査会社):Global Markets Direct
・発行日:2017年11月14日
・ページ数:171
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥224,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥448,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥672,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
当調査レポートでは、世界における大腸菌感染症の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。
・イントロダクション
・大腸菌感染症の概要
・大腸菌感染症治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・大腸菌感染症パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・企業別、開発中の製品
・大学/研究機関別、研究中の製品
・大腸菌感染症治療薬開発に取り組んでいる企業:企業別製品パイプライン
・大腸菌感染症治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Escherichia coli Infections – Pipeline Review, H2 2017

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Escherichia coli Infections – Pipeline Review, H2 2017, provides an overview of the Escherichia coli Infections (Infectious Disease) pipeline landscape.

Escherichia coli (E. coli) bacteria normally live in the intestines of healthy people and animals. Escherichia coli infections are caused by coming into contact with the feces, or stool, of humans or animals or drink water or eat food that has been contaminated by feces. Symptoms include diarrhea, which may range from mild and watery to severe and bloody, abdominal cramping, pain or tenderness, nausea and vomiting. The predisposing factors include age, weakened immune systems and eating certain types of food like undercooked hamburger, unpasteurized milk, apple juice or cider and soft cheeses made from raw milk. Treatment includes antibiotics and healthy life style.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Escherichia coli Infections – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Escherichia coli Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Escherichia coli Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Escherichia coli Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 2, 1, 31 and 13 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 7 and 14 molecules, respectively.

Escherichia coli Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Escherichia coli Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Escherichia coli Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Escherichia coli Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Escherichia coli Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Escherichia coli Infections (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Escherichia coli Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Escherichia coli Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Escherichia coli Infections – Overview 8
Escherichia coli Infections – Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Pipeline by Universities/Institutes 14
Products under Development by Companies 16
Products under Development by Universities/Institutes 19
Escherichia coli Infections – Therapeutics Assessment 21
Assessment by Target 21
Assessment by Mechanism of Action 24
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Escherichia coli Infections – Companies Involved in Therapeutics Development 31
Adenium Biotech ApS 31
AstraZeneca Plc 31
Atterx Biotherapeutics Inc 31
AvidBiotics Corp 32
ContraFect Corp 32
Debiopharm International SA 33
Emergent BioSolutions Inc 33
F. Hoffmann-La Roche Ltd 34
Hsiri Therapeutics LLC 34
ImmunoClin Corp 35
Immuron Ltd 35
Innovation Pharmaceuticals Inc 35
Johnson & Johnson 36
Kyorin Pharmaceutical Co Ltd 36
Melinta Therapeutics Inc 37
Merck & Co Inc 37
Microbiotix Inc 38
Nabriva Therapeutics plc 38
Navigen Inc 39
Nosopharm SAS 39
Novabiotics Ltd 39
Paratek Pharmaceuticals Inc 40
Phico Therapeutics Ltd 40
PTC Therapeutics Inc 41
Recce Ltd 41
Sealife PHARMA GMBH 42
Syntiron LLC 42
Tetraphase Pharmaceuticals Inc 42
Venus Medicine Research Center 43
Escherichia coli Infections – Drug Profiles 44
A-3APO – Drug Profile 44
AA-139 – Drug Profile 46
AM-8722 – Drug Profile 47
ASN-200 – Drug Profile 48
AvR-2V10 – Drug Profile 49
BC-7634 – Drug Profile 51
BC-9074 – Drug Profile 52
BC-9529 – Drug Profile 53
BC-9563 – Drug Profile 54
BIZ-20131 – Drug Profile 55
BIZ-20132 – Drug Profile 56
BIZ-20133 – Drug Profile 57
CA-824 – Drug Profile 58
CC-1807 – Drug Profile 59
CF-301 – Drug Profile 60
Debio-1454 – Drug Profile 65
delafloxacin meglumine – Drug Profile 66
EBX-004 – Drug Profile 76
Escherichia coli vaccine – Drug Profile 77
Escherichia coli vaccine – Drug Profile 78
ETEC [strain B7A] vaccine – Drug Profile 79
ETEC vaccine – Drug Profile 80
EV-035 – Drug Profile 81
GN Snare – Drug Profile 83
GN-4474 – Drug Profile 84
GYR-12 – Drug Profile 85
HT-07 – Drug Profile 86
infectious disease vaccine – Drug Profile 87
interleukin-22 – Drug Profile 88
JNJ-63871860 – Drug Profile 89
JSM-11 – Drug Profile 91
MBX-2319 – Drug Profile 92
MDN-0057 – Drug Profile 93
mirandamycin – Drug Profile 95
NBTI-5463 – Drug Profile 96
NCL-195 – Drug Profile 97
NOSO-95179 – Drug Profile 98
NP-432 – Drug Profile 99
omadacycline tosylate – Drug Profile 100
Onc-72 – Drug Profile 112
P-100031 – Drug Profile 113
Peptides for Infectious Diseases – Drug Profile 114
Polysaccharides for Bacterial Infections – Drug Profile 115
Proteins for Infectious Diseases – Drug Profile 116
PT-5 – Drug Profile 117
RECCE-327 – Drug Profile 118
Recombinant Protein for Escherichia Coli Infections – Drug Profile 121
RX-04 – Drug Profile 122
RXP-873 – Drug Profile 125
SE-1 – Drug Profile 127
Shigetec – Drug Profile 128
SLP-0901 – Drug Profile 129
SLP-0905 – Drug Profile 130
Small Molecule for Bacterial Infections – Drug Profile 131
Small Molecule for Malaria and Bacterial Infections – Drug Profile 132
Small Molecule to Activate IL-10 for Bacterial Infections and Crohn’s Disease – Drug Profile 133
Small Molecule to Inhibit LpxC for Gram-Negative Bacterial Infections – Drug Profile 134
Small Molecules for Escherichia coli Infections – Drug Profile 135
Small Molecules for Gram-Negative Bacterial Infections – Drug Profile 136
Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections – Drug Profile 137
Small Molecules to Inhibit DbpA for Escherichia coli Infections – Drug Profile 138
Small Molecules to Inhibit DNA Gyrase for Gram Negative Bacterial Infections – Drug Profile 139
Small Molecules to Inhibit RecA for Bacterial Infections – Drug Profile 140
SPR-741 – Drug Profile 141
Synthetic Peptide for Oncology and Infectious Disease – Drug Profile 144
Synthetic Peptide to Antagonize TLR-4 for Oncology, Immunology and Infectious Disease – Drug Profile 145
Synthetic Peptide to Target Bacterial Cell Membrane for Gram Negative and Gram Positive Bacterial Infections – Drug Profile 146
Synthetic Peptides for Escherichia Coli Infections – Drug Profile 147
Synthetic Peptides for Infectious Disease – Drug Profile 148
tebipenem pivoxil – Drug Profile 149
TN-5 – Drug Profile 150
TP-6076 – Drug Profile 151
VRE-001 – Drug Profile 153
Escherichia coli Infections – Dormant Projects 154
Escherichia coli Infections – Discontinued Products 157
Escherichia coli Infections – Product Development Milestones 158
Featured News & Press Releases 158
Appendix 165
Methodology 165
Coverage 165
Secondary Research 165
Primary Research 165
Expert Panel Validation 165
Contact Us 165
Disclaimer 166

List of Tables
Number of Products under Development for Escherichia coli Infections, H2 2017 14
Number of Products under Development by Companies, H2 2017 16
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 17
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 18
Number of Products under Development by Universities/Institutes, H2 2017 19
Products under Development by Companies, H2 2017 21
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 22
Products under Development by Companies, H2 2017 (Contd..2), H2 2017 23
Products under Development by Universities/Institutes, H2 2017 24
Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 25
Number of Products by Stage and Target, H2 2017 27
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 28
Number of Products by Stage and Mechanism of Action, H2 2017 30
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 31
Number of Products by Stage and Route of Administration, H2 2017 33
Number of Products by Stage and Molecule Type, H2 2017 35
Escherichia coli Infections - Pipeline by Adenium Biotech ApS, H2 2017 36
Escherichia coli Infections - Pipeline by AstraZeneca Plc, H2 2017 36
Escherichia coli Infections - Pipeline by Atterx Biotherapeutics Inc, H2 2017 37
Escherichia coli Infections - Pipeline by AvidBiotics Corp, H2 2017 37
Escherichia coli Infections - Pipeline by ContraFect Corp, H2 2017 38
Escherichia coli Infections - Pipeline by Debiopharm International SA, H2 2017 38
Escherichia coli Infections - Pipeline by Emergent BioSolutions Inc, H2 2017 39
Escherichia coli Infections - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017 39
Escherichia coli Infections - Pipeline by Hsiri Therapeutics LLC, H2 2017 39
Escherichia coli Infections - Pipeline by ImmunoClin Corp, H2 2017 40
Escherichia coli Infections - Pipeline by Immuron Ltd, H2 2017 40
Escherichia coli Infections - Pipeline by Innovation Pharmaceuticals Inc, H2 2017 41
Escherichia coli Infections - Pipeline by Johnson & Johnson, H2 2017 41
Escherichia coli Infections - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2017 42
Escherichia coli Infections - Pipeline by Melinta Therapeutics Inc, H2 2017 42
Escherichia coli Infections - Pipeline by Merck & Co Inc, H2 2017 43
Escherichia coli Infections - Pipeline by Microbiotix Inc, H2 2017 43
Escherichia coli Infections - Pipeline by Nabriva Therapeutics plc, H2 2017 44
Escherichia coli Infections - Pipeline by Navigen Inc, H2 2017 44
Escherichia coli Infections - Pipeline by Nosopharm SAS, H2 2017 44
Escherichia coli Infections - Pipeline by Novabiotics Ltd, H2 2017 45
Escherichia coli Infections - Pipeline by Paratek Pharmaceuticals Inc, H2 2017 45
Escherichia coli Infections - Pipeline by Phico Therapeutics Ltd, H2 2017 46
Escherichia coli Infections - Pipeline by PTC Therapeutics Inc, H2 2017 46
Escherichia coli Infections - Pipeline by Recce Ltd, H2 2017 46
Escherichia coli Infections - Pipeline by Sealife PHARMA GMBH, H2 2017 47
Escherichia coli Infections - Pipeline by Syntiron LLC, H2 2017 47
Escherichia coli Infections - Pipeline by Tetraphase Pharmaceuticals Inc, H2 2017 48
Escherichia coli Infections - Pipeline by Venus Medicine Research Center, H2 2017 48
Escherichia coli Infections - Dormant Projects, H2 2017 159
Escherichia coli Infections - Dormant Projects, H2 2017 (Contd..1), H2 2017 160
Escherichia coli Infections - Dormant Projects, H2 2017 (Contd..2), H2 2017 161
Escherichia coli Infections - Discontinued Products, H2 2017 162

List of Figures
Number of Products under Development for Escherichia coli Infections, H2 2017 14
Number of Products under Development by Companies, H2 2017 15
Number of Products under Development by Universities/Institutes, H2 2017 19
Number of Products by Top 10 Targets, H2 2017 26
Number of Products by Stage and Top 10 Targets, H2 2017 26
Number of Products by Top 10 Mechanism of Actions, H2 2017 29
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 29
Number of Products by Top 10 Routes of Administration, H2 2017 32
Number of Products by Stage and Top 10 Routes of Administration, H2 2017 32
Number of Products by Top 10 Molecule Types, H2 2017 34
Number of Products by Stage and Top 10 Molecule Types, H2 2017 34

【レポートのキーワード】

大腸菌感染症

★調査レポート[大腸菌感染症:治療薬開発パイプライン分析] (コード:GMDHC9885IDB)販売に関する免責事項を必ずご確認ください。
★調査レポート[大腸菌感染症:治療薬開発パイプライン分析]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆